aprott Latigo Biotherapeutics ( LTGO ), a clinical-stage biopharma focused on developing non-opioid pain medicines, rose sharply on its first day of trading after an upsized initial public offering that raised over $300M.
Dulan Lokuwithana is an Editor for Breaking News at NewsBreak. He specializes in the intersection of finance and healthcare, covering topics such as pharmaceutical manufacturing, regulation, and advancements in gene therapy, immunology, and oncology. Dulan's insights and analyses are featured in prominent outlets like NewsBreak and Seeking Alpha.
















